Loading...

About Carolina BioOncology Institute

Carolina BioOncology Institute is reimagining access to groundbreaking cancer treatments, a disruptive approach to bench-to-bedside medicine. Our unique business model leverages curated access to Phase I Clinical Trials with on site research and clinical laboratory support for the treatment of human disease.

Patient & Sponsor Services

Clinical Trials

Patients participating in a clinical trial have the opportunity to receive new research treatments before they are widely available. With Phase I clinical trial capabilities at our facility in Huntersville, NC, we’re able to quickly enroll patients in the newest trials and provide the highest quality of patient care in a community-based setting.

Learn More

CLIA Laboratory Services

Our on site Clinical Laboratory can provide routine patient sample analyses including hematology, urinalysis, metabolic testing, and other diagnostic services. The facility is also high-complexity certified in Immunology and can perform CELLSEARCH CTC enumeration and COVID-19 screening as requested or provider-ordered.

Learn More

Contract Research

Human Applications Lab (HAL) staff perform translational Tumor Immunology research for internal projects and biopharmaceutical sponsors. Expert staff are trained in GDP, GLP, and cGMP regulations in order to provide services like cell processing, technology transfer, process scale-up, and other IND-enabling solutions.

Learn More

In The News

Mother says immunotherapy kept her alive and allowed her to be there for her son

Spectrum News 1

Full Article

Cancer immunotherapy patient living longer than expected

WCNC

Full Article

Featured Practice: Carolina BioOncology Institute & BioCytics Human Applications Lab

Charlotte Mag Content Studio

Full Article

Highlights from the September 9th Event UNC Charlotte Dubois Center Through NCBiotech

The Center for Biomedical Engineering and Science

Full Article

Unlocking The Common Issues of Cancer Therapies – featuring Dr. John Powderly

One Cancer Place

Full Article

Title21 Customer Spotlight: Carolina BioOncology Institute

Title21 Health Solutions

Full Article

National Minority Quality Forum’s announces a collaboration with Carolina BioOncology Institute

NMQF By Adjoa Kyerematen

NMQF, Carolina BioOncology, and BioCytics are collaborating to create a national registry and biorepository for CSSI, collecting critical clinical, genetic, and demographic data from 20 communities. This biorepository will support research on cancer risk factors, driving logistical changes to ease the development and deployment of new detection technologies and precision treatments. De-identified data will be accessible to researchers, helping ensure that advancements in cancer care reach underserved communities. The findings will be used to improve local cancer care logistics, advancing the Cancer Moonshot’s goal of reducing cancer mortality in these populations by addressing bottlenecks through a data-driven approach.

Full Article

Expanding Cellular Therapies in a Community Setting: An Interview with Dr. John Powderly, II

Biomedical Sciences Symposium 2024

Dr. John Powderly II, Medical Oncologist, Certified Physician Investigator, and Founder and President of Carolina BioOncology Institute and BioCytics, realized early on in his medical career that he felt a strong passion for cellular therapies. As a 4th year medical student interning under the mentorship of immunotherapy pioneer Dr. Steven Rosenberg at the National Cancer Institute, Dr. Powderly first started working with cellular therapies in the mid-1990s and has since dedicated his career to this therapeutic area. Shortly after completing his oncology fellowship at University of North Carolina, Chapel Hill, Dr. Powderly founded the Carolina BioOncology Institute (CBOI) in 2005 as a community-based clinic specializing in early phase immunotherapy and cellular therapy trials. Located in Charlotte, North Carolina, CBOI is the only independent phase I cancer center with cellular manufacturing capabilities on the east coast and serves as a regional hub for access to phase I trials in the community setting.

Full Article

View Our Facilities